HanchorBio's lead candidate HCB101, a third-generation CD47-targeting immunotherapy, demonstrates enhanced efficacy in both hematologic and solid tumors with 100-fold higher CD47 affinity than previous generations.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.